Back to User profile » Prof. Dr. Giacomo Bruno
Papers published by Prof. Dr. Giacomo Bruno:
Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
Torre E, Di Matteo S, Martinotti C, Bruno GM, Cabrino A, Fogliati EL, Giusti A, Barbieri M, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2026, 18:585328
Published Date: 1 May 2026
Health and Economic Advantages Associated With the Use of TachoSil: An Update of Systematic Review
Colombo GL, Droghetti A, Di Matteo S, Ottenjann H, Bruno GM
Therapeutics and Clinical Risk Management 2025, 21:257-271
Published Date: 1 March 2025
Cost–Benefit Analysis of in vivo Reflectance Confocal Microscopy for Melanoma Diagnosis in a Real-World Clinical Setting
Bruno GM, Di Matteo S, Longo C, Stanganelli I, Farnetani F, Borsari S, Mazzoni L, Ciardo S, Raucci M, Magi S, Bassoli S, Spadafora M, Mandel VD, Casari A, Chester J, Kaleci S, Colombo GL, Pellacani G
Risk Management and Healthcare Policy 2025, 18:163-172
Published Date: 15 January 2025
Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Di Matteo S, Freilone R, Bruno GM, Notaro R, Moumene S, Martone N, Teruzzi C, Ciccarone A, Colombo GL
ClinicoEconomics and Outcomes Research 2024, 16:225-232
Published Date: 11 April 2024
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
Colombo GL, Valentino MC, Fabi A, Dieci MV, Caruggi M, Bruno GM, Lombardi G, Di Matteo S
Therapeutics and Clinical Risk Management 2023, 19:301-312
Published Date: 28 March 2023
Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
Torre E, Di Matteo S, Bruno GM, Martinotti C, Valentino MC, Testino G, Rebora A, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2022, 14:607-618
Published Date: 14 September 2022
Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus
Torre E, Colombo GL, Di Matteo S, Martinotti C, Valentino MC, Rebora A, Cecoli F, Monti E, Galimberti M, Di Bartolo P, Gaggioli G, Bruno GM
ClinicoEconomics and Outcomes Research 2021, 13:503-518
Published Date: 14 June 2021
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2020, 12:177-189
Published Date: 8 April 2020
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM
Risk Management and Healthcare Policy 2020, 13:43-53
Published Date: 22 January 2020
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM
ClinicoEconomics and Outcomes Research 2018, 10:477-491
Published Date: 30 August 2018
Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
Torre E, Bruno GM, Di Matteo S, Martinotti C, Oselin M, Valentino MC, Parodi A, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2018, 10:413-421
Published Date: 26 July 2018
The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis
Colombo GL, Di Matteo S, Martinotti C, Oselin M, Bruno GM, Beghi GM
ClinicoEconomics and Outcomes Research 2018, 10:75-82
Published Date: 23 January 2018
Economic burden of Clostridium difficile in five hospitals of the Florence health care system in Italy
Poli A, Di Matteo S, Bruno GM, Fornai E, Valentino MC, Colombo GL
Risk Management and Healthcare Policy 2015, 8:207-213
Published Date: 18 November 2015
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation
Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C
Patient Related Outcome Measures 2015, 6:53-60
Published Date: 17 February 2015
Economic and outcomes consequences of TachoSil®: a systematic review
Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM
Vascular Health and Risk Management 2014, 10:569-576
Published Date: 10 September 2014
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A
Therapeutics and Clinical Risk Management 2014, 10:9-15
Published Date: 18 December 2013
Syringeless power injector versus dual-syringe power injector: economic evaluation of user performance, the impact on contrast enhanced computed tomography (CECT) workflow exams, and hospital costs
Colombo GL, Bergamo Andreis IA, Di Matteo S, Bruno GM, Mondellini C
Medical Devices: Evidence and Research 2013, 6:169-174
Published Date: 5 November 2013
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
Colombo GL, Di Matteo S, Bruno G, Girolomoni G, Vena GA
ClinicoEconomics and Outcomes Research 2012, 4:261-268
Published Date: 13 September 2012
Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
Colombo GL, Di Matteo S, Bruno G
Substance Abuse and Rehabilitation 2012, 3:73-79
Published Date: 17 July 2012